Thrombodynamics test efficacy in predicting thromboembolic complications in patients with lymphoproliferative disorders

Cover Page

Cite item

Full Text

Abstract

Background. Patients with lymphoproliferative disorders (LPD) are at increased risk of developing venous thromboembolic complications (VTEC). Existing risk assessment systems for VTEC (Khorana, Vienna, ThroLy, etc.) do not have sufficient prognostic accuracy in this patient population. The thrombodynamics test may improve the prognosis of VTEC and optimize the prophylactic use of anticoagulants in these patients.

Aim. To evaluate thrombodynamics test efficacy in assessing the risk of venous VTEC in LPD patients.

Materials and methods. Medical data of 990 patients with LPD who received treatment at the Kirov Research Institute of Hematology and Blood Transfusion from 2019 to 2021 were analyzed. Coagulation parameters were evaluated at admission, as well as the risk of developing VTEC by prognostic scales Khorana, Vienna, ThroLy, SAVED, and Padua. Data are presented as median and interquartile range. Mann–Whitney U test was used to compare two independent groups. Correlation was determined using Spearman’s rank correlation. Logistic regression was used to determine dependencies. The diagnostic value of laboratory tests was established through ROC analysis.

Results. In the overall cohort of LPD patients, the incidence of VTEC was 2.1 %. Screening coagulogram parameters in these patients did not exceed reference values. Patients with LPD who developed VTEC initially showed a significant increase in clot velocity (V), initial growth velocity (Vi), and clot size (Cs). It was found that the presence of spontaneous clots significantly increased the chances of developing a thrombotic event (odds ratio 3.99; 95 % confidence interval 1.56–10.22; p = 0.004). It was also determined that V velocity is an independent predictor of VTEC (adjusted odds ratio 1.053; 95 % confidence interval 1.016–1.090; p = 0.0046). The AUC determined by ROC analysis for the V parameter was 0.722 (threshold value 30.7 μm/min sensitivity 81 %, specificity 57.4 %).

Conclusion. Clot growth velocity is the most informative parameter of thrombodynamics test in predicting VTEC.

About the authors

S. V. Ignatyev

Kirov Research Institute of Hematology and Blood Transfusion, Federal Medical and Biological Agency

Author for correspondence.
Email: feb74@yandex.ru
ORCID iD: 0000-0002-8457-2967

Sergey V. Ignatiev 

72 Krasnoarmeyskaya St., Kirov, 610027

Russian Federation

A. V. Lyanguzov

Kirov Research Institute of Hematology and Blood Transfusion, Federal Medical and Biological Agency

ORCID iD: 0000-0001-5509-5308

72 Krasnoarmeyskaya St., Kirov, 610027

Russian Federation

I. V. Paramonov

Kirov Research Institute of Hematology and Blood Transfusion, Federal Medical and Biological Agency

ORCID iD: 0000-0002-7205-912X

72 Krasnoarmeyskaya St., Kirov, 610027

Russian Federation

References

  1. Metharom P., Falasca M., Berndt M.C. The history of Armand Trousseau and cancer-associated thrombosis. Cancers 2019;11(2):158. doi: 10.3390/cancers11020158
  2. Hohaus S., Bartolomei F., Cuccaro A. et al. Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers 2020;12(5):1291. doi: 10.3390/cancers12051291
  3. Gangaraju R., Chen Y., Hageman L. et al. Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation. Cancer 2019;125(24):4498–508. doi: 10.1002/cncr.32488
  4. Kekre N., Kim H.T., Ho V.T. et al. Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 2017;102(7):1185–91. doi: 10.3324/haematol.2017.164012
  5. Lyman G.H., Culakova E., Poniewierski M.S., Kuderer N.M. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res 2018;164(Suppl 1):S112–8. doi: 10.1016/j.thromres.2018.01.028
  6. Noble S., Pasi J. Epidemiology and pathophysiology of cancerassociated thrombosis. Br J Cancer 2010;102(Suppl 1):S2–9. doi: 10.1038/sj.bjc.6605599
  7. Angelini D.E., Radivoyevitch T., McCrae K.R., Khorana A.A. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol 2019;94(7):780–5. doi: 10.1002/ajh.25494
  8. Prandoni P., Lensing A.W.A., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484–8. doi: 10.1182/blood-2002-01-0108
  9. Callow C.R., Swindell R., Randall W., Chopra R. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol 2002;118(2):677–82. doi: 10.1046/j.1365-2141.2002.03616.x
  10. Khorana A.A., Kuderer N.M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111(10):4902–7. doi: 10.1182/blood-2007-10-116327
  11. Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116(24):5377–82. doi: 10.1182/blood-2010-02-270116
  12. Antic D., Milic N., Nikolovski S. et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol 2016;91(10):1014–9. doi: 10.1002/ajh.24466
  13. Barbar S., Noventa F., Rossetto V. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010;8(11):2450–7. doi: 10.1111/j.1538-7836.2010.04044.x
  14. Le Gal G., Righini M., Roy P.M. et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Int Med 2006;144(3):165–71. doi: 10.7326/0003-4819-144-3-200602070-00004
  15. Palumbo A., Rajkumar S.V., Dimopoulos M.A. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22(2):414–23. doi: 10.1038/sj.leu.2405062
  16. Caprini J.A. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005;51(2–3):70–8. doi: 10.1016/j.disamonth.2005.02.003
  17. Kekre N., Connors J.M. Venous thromboembolism incidence in hematologic malignancies. Blood Rev 2019;33:24–32. doi: 10.1016/j.blre.2018.06.002
  18. Santi R.M., Ceccarelli M., Bernocco E. et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). Thromb Haemost 2017. doi: 10.1160/TH16-11-0895
  19. George D., Agnelli G., Fisher W. et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVEONCO. 2011. P. 96.
  20. Macbeth F., Noble S., Evans J. et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol 2016;34(5):488–94. doi: 10.1200/JCO.2015.64.0268
  21. Rupa-Matysek J., Brzeźniakiewicz-Janus K., Gil L. et al. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med 2018;7(7):2868–75. doi: 10.1002/cam4.1540
  22. Ignatiev S.V., Lyanguzov A.V., Fokina E.S. et al. Issue of predicting the risk of thromboembolic complications in patients with lymphoproliferative diseases. Onkogematologiya = Oncohematology 2022;17(2):134–40. (In Russ.). doi: 10.17650/1818-8346-2022-17-2-134-140
  23. Balandina A.N., Koltsova E.M., Shibeko A.M. et al. Thrombodynamics: a new method to the diagnosis of hemostasis system disorders. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2018;17(4):114–26. (In Russ.). doi: 10.24287/1726-1708-2018-17-4-114-126
  24. Soshitova N.P., Karamzin S.S., Balandina A.N. et al. Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics. Blood Coagul Fibrinolysis 2012;23(6):498–507. doi: 10.1097/MBC.0b013e328352e90e
  25. Gracheva M.A., Balandina A.N., Ataullakhanov F.I. Comparison of responses of integrated and screening tests for hemostasis assessment to various coagulation states in models in vitro. Tromboz, gemostaz i reologiya = Thrombosis, Hemostasis and Rheology 2016;(4):64–71. (In Russ.).
  26. Dudina I.A., Koltsova E.M., Nigmatullina I.E. et al. Using a thrombodynamics test for diagnostics of hypercoagulation and prediction of thromboembolic complications in patients with malignant tumors. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2024;69(1):20–31. (In Russ.). doi: 10.35754/0234-5730-2024-69-1-20-31
  27. Caruso V., Di Castelnuovo A., Meschengieser S. et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood 2010;115(26):5322–8. doi: 10.1182/blood-2010-01-258624
  28. Grover S.P., Hisada Y.M., Kasthuri R.S. et al. Cancer therapyassociated thrombosis. Arterioscler Thromb Vasc Biol 2021;41(4):1291–305. doi: 10.1161/ATVBAHA.120.314378
  29. Li X., Hou S.L., Li X. et al. Risk factors of thromboembolism in lymphoma patients undergoing chemotherapy and its clinical significance. Clin Appl Thromb Hemost 2021;27:10760296211037923. doi: 10.1177/10760296211037923
  30. Mann K.G., Brummel K., Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1(7):1504–14. doi: 10.1046/j.1538-7836.2003.00298.x
  31. Lecut C., Peters P., Massion P.B., Gothot A. [Is there a place for thrombin generation assay in routine clinical laboratory?]. Annal De Biol Clin 2015;73(2):137–49. doi: 10.1684/abc.2014.1018
  32. Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016;62(5):699–707. doi: 10.1373/clinchem.2015.248625
  33. Duarte R.C.F., Ferreira C.N., Rios D.R.A. et al. Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations. Rev Bras Hematol Hemoter 2017;39(3):259–65. doi: 10.1016/j.bjhh.2017.03.009
  34. Lim H.Y., O’Malley C., Donnan G. et al. A review of global coagulation assays. Is there a role in thrombosis risk prediction? Thromb Res 2019;179:45–55. doi: 10.1016/j.thromres.2019.04.033
  35. Lipets E.N., Ataullakhanov F.I. Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thromb J 2015;13(1):4. doi: 10.1186/s12959-015-0038-0
  36. Hemker H.C., Wielders S., Kessels H., Béguin S. Continuous regist ration of thrombin generation in plasma, its use for the determina tion of the thrombin potential. Thromb Haemost 1993;70(4):617–64.
  37. Park M.S., Martini W.Z., Dubick M.A. et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009;67(2):266–75; discussion 275–6. doi: 10.1097/TA.0b013e3181ae6f1c
  38. Toukh M., Siemens D.R., Black A. et al. Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer. Thromb Res 2014;133(1):88–95. doi: 10.1016/j.thromres.2013.10.007
  39. Lipets E., Vlasova O., Margolin O. et al. Circulating contactpathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PLoS One 2014;9(1):e87692. doi: 10.1371/journal.pone.0087692
  40. Bertaggia Calderara D., Aliotta A., Zermatten M.G. et al. Hypercoagulability in obese patients accurately identified by combinations of global coagulation assay parameters. Thromb Res 2020;187:91–102. doi: 10.1016/j.thromres.2020.01.012

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.